We have located links that may give you full text access.
Angiopoietin-2/Tie2 inhibition by regorafenib associates with striking response in a patient with aggressive hepatocellular carcinoma.
Hepatology : Official Journal of the American Association for the Study of Liver Diseases 2019 Februrary 26
Despite surveillance, hepatocellular carcinoma (HCC) often presents at such an advanced stage that only systemic therapy with sorafenib is feasible. However, aggressive HCCs bearing the neoangiogenic transcriptomic signature (TS)(1) are scarcely sensitive to sorafenib, which has no activity against the leading gene of the signature Angiopoietin-2 (Ang-2). The recently approved HCC drug regorafenib could instead possess some pharmacologic activity against it (2,3). We report a case of massive aggressive TS-positive HCC had a striking response to regorafenib. This article is protected by copyright. All rights reserved.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app